Evidence map›Paper›PMID 26256637›Full record

ArticleLeukemia2015

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

J C Strefford, L Kadalayil, J Forster, M J J Rose-Zerilli, A Parker, T T Lin, N Heppel, K Norris, A Gardiner, Z Davies and 11 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Role of telomere length in human carcinogenesis (Review).International journal of oncology · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Chronic Lymphocytic Leukemia.Cold Spring Harbor perspectives in medicine · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

J C StreffordCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
L KadalayilGenetic Epidemiology and Bioinformatics, Faculty of Medicine, University of Southampton, Southampton, UK.
J ForsterCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
M J J Rose-ZerilliCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
A ParkerDepartment of Pathology, Royal Bournemouth Hospital, Bournemouth, UK.
T T LinCLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
N HeppelCLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
K NorrisCLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
A GardinerDepartment of Pathology, Royal Bournemouth Hospital, Bournemouth, UK.
Z DaviesDepartment of Pathology, Royal Bournemouth Hospital, Bournemouth, UK.
D Gonzalez de CastroHaemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
M ElseHaemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
A J SteeleCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
H ParkerCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
T StankovicDivision of Cancer Sciences, School of Medicine, University of Birmingham, Birmingham, UK.
C PepperCLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
C FeganCLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
D BairdCLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
A CollinsGenetic Epidemiology and Bioinformatics, Faculty of Medicine, University of Southampton, Southampton, UK.
D CatovskyHaemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
D G OscierCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Funding

Bloodwise 11052Bloodwise 12036
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TelomereDisease ProgressionGenes, p53HumansImmunoglobulin Heavy ChainsLeukemia, Lymphocytic, Chronic, B-CellMutationImmunoglobulin Heavy Chains

Identifiers

PMID26256637
PMCPMC4676082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.